Petros Pharmaceuticals Stock Today
| PTPI Stock | USD 0.07 0 3.95% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Petros Pharmaceuticals is trading at 0.073 as of the 22nd of March 2025. This is a 3.95 percent decrease since the beginning of the trading day. The stock's open price was 0.076. Petros Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of December 2020 | Category Healthcare | Classification Health Care |
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on mens health therapeutics. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 25.27 M outstanding shares of which 2.1 M shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover. More on Petros Pharmaceuticals
Moving together with Petros Stock
Moving against Petros Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Petros Stock Highlights
| President Officer | Fady MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsPetros Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Petros Pharmaceuticals' financial leverage. It provides some insight into what part of Petros Pharmaceuticals' total assets is financed by creditors.
| |||||
Petros Pharmaceuticals (PTPI) is traded on NASDAQ Exchange in USA. It is located in 1185 Avenue of the Americas, New York, NY, United States, 10036 and employs 21 people. Petros Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.92 M. Petros Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 25.27 M outstanding shares of which 2.1 M shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover.
Petros Pharmaceuticals currently holds about 13.3 M in cash with (7.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Petros Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationPetros Pharmaceuticals owns a total of 25.27 Million outstanding shares. Petros Pharmaceuticals holds 6.81 pct. of its outstanding shares held by insiders and 10.28 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Petros Ownership Details
Petros Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 36.2 K | |
| Two Sigma Securities, Llc | 2024-12-31 | 0.0 | |
| Vanguard Group Inc | 2024-12-31 | 31.8 K | |
| Blackrock Inc | 2024-12-31 | 16.1 K | |
| Ubs Group Ag | 2024-12-31 | 13 K | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 200 | |
| Group One Trading, Lp | 2024-12-31 | 79.0 | |
| Bank Of America Corp | 2024-12-31 | 75.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 19.0 | |
| 1832 Asset Management L.p | 2024-09-30 | 0.0 | |
| Tower Research Capital Llc | 2024-12-31 | 0.0 |
Petros Pharmaceuticals Historical Income Statement
Petros Stock Against Markets
Petros Pharmaceuticals Corporate Management
| Mitchell MBA | VP Officer | Profile | |
| Keith Lavan | Advisor | Profile | |
| John Shulman | Executive Board | Profile | |
| Robert Weinstein | Interim Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets | Return On Equity |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.